Merck’s Positive CETP Inhibitor Study Results Could Bode Well For Drug Class
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm has not made a final decision to move anacetrapib into Phase III trials, Merck tells "The Pink Sheet" DAILY.